Approved, compounded, and unapproved: why the distinction matters
A plain-language guide to product status, quality review, and avoiding false equivalence.
Educational information only — not medical advice. This page does not diagnose conditions, recommend treatment, or replace care from a qualified clinician. The Peptide Center uses an evidence-first editorial process: regulatory sources, trial registries, and peer-reviewed research take priority; uncertainty is stated rather than filled with promises.
FDA approval applies to a specific product for specific labeled uses. Compounded drugs are not FDA approved, and an unapproved product has not undergone FDA review as a complete product for safety, effectiveness, and quality. These categories should not be treated as interchangeable.
References
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
5-Amino-1MQ
An evidence-first reference for reading claims and source material about 5-Amino-1MQ.
Open resourcePeptide brief5-Amino-1MQ / SLU-PP-332
An evidence-first reference for reading claims and source material about 5-Amino-1MQ / SLU-PP-332.
Open resourcePeptide briefAlpha-Klotho mAb
An evidence-first reference for reading claims and source material about Alpha-Klotho mAb.
Open resourcePeptide briefAOD-9604
An evidence-first reference for reading claims and source material about AOD-9604.
Open resourcePeptide briefAOD-9604: interpreting a fragment-peptide claim
A framework for evaluating evidence and regulatory claims around an hGH-fragment research compound.
Open resourcePeptide briefARA-290
An evidence-first reference for reading claims and source material about ARA-290.
Open resourceArticleFDA approved, compounded, and unapproved are not synonyms
A plain-language map of product categories that are often blurred in peptide discussions.
Open resourceArticleHow to read a peptide study without overclaiming
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Open resource